Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma

International audiencePurpose This study aimed at identifying prior therapy dosimetric parameters using 99mTc-labeled macro-aggregates of albumin (MAA) that are associated with contralateral hepatic hypertrophy occurring after unilobar radioembolization of hepatocellular carcinoma (HCC) performed with Y-90-loaded glass microspheres. Methods The dosimetry data of 73 HCC patients were collected prior to the treatment with Y-90-loaded microspheres for unilateral disease. The injected liver dose (ILD), the tumor dose (TD) and healthy injected liver dose (HILD) were calculated based on MAA quantification. Following treatment, the maximal hypertrophy (MHT) of an untreated lobe was calculated. Results Mean MHT was 35.4 +/- 40.4%. When using continuous variables, the MHT was not correlated with any tested variable, i.e., injected activity, ILD, HILD or TD except with a percentage of future remnant liver (FRL) following the Y-90-microspheres injection (r = -0.56). MHT >= 10% was significantly more frequent for patients with HILD >= 88 Gy, (52% of the cases), i.e., in 92.2% versus 65.7% for HILD = 10% was also significantly more frequent for patients with a TD >= 205 Gy and a tumor volume (VT) >= 100 cm(3) in patients with initial FRL = 10% was seen in 83.9% for patients with either an HILD >= 88 Gy or a TD >= 205 Gy for tumors larger than 100cm(3) (85% of the cases), versus only 54.5% (p = 0.0265) for patients with none of those parameters. MHT >= 10% was also associated with FRL and the ChildPugh score. Using multivariate analysis, the Child-Pugh score (p = 10%. Conclusion This study demonstrates for the first time that HILD is significantly associated with liver hypertrophy. There is also an impact of high tumor doses in large lesions in one subgroup of patients. Larger prospective studies evaluating the MAA dosimetric parameters have to be conducted to confirm these promising results